People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Earlier phases of the trial showed promising results, with a single 25mg dose of COMP360 psilocybin, combined with psychological support, significantly reducing depressive symptoms after three weeks, ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...